The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial’s Impact

References

• Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–162. doi:10.1097/JTO.0000000000000033
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Non-small cell lung cancer (version 3.2023). Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450. Accessed June 28, 2023.
   Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. doi:10.1056/NEJMoa1913662
   PubMed Web of Science ®Google Scholar
• Akli A, Girard N, Fallet V, et al. Histomolecular resistance mechanisms to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer: a multicentric retrospective French study. Target Oncol. 2022;17(6):675–682. doi:10.1007/s11523-022-00915-9
   PubMed Web of Science ®Google Scholar
• Nie K, Jiang H, Zhang C, et al. Mutational profiling of non-small-cell lung cancer resistant to osimertinib using next-generation sequencing in Chinese patients. Biomed Res Int. 2018;2018:9010353. doi:10.1155/2018/9010353
   PubMed Web of Science ®Google Scholar
• Planchard D, Feng PH, Karaseva N, et al. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open. 2021;6(5):100271. doi:10.1016/j.esmoop.2021.100271
   PubMed Web of Science ®Google Scholar
• Cho BC, Felip E, Hayashi H, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2022;18(6):639–647. doi:10.2217/fon-2021-0923
   PubMed Web of Science ®Google Scholar
• Lisberg A, Cummings A, Goldman JW, et al. A Phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol. 2018;13(8):1138–1145. doi:10.1016/j.jtho.2018.03.035
   PubMed Web of Science ®Google Scholar
• Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2980–2987. doi:10.1200/JCO.2016.66.9929
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi:10.1016/S0140-6736(15)01281-7
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, Phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–1846. doi:10.1016/S0140-6736(16)00587-0
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi:10.1056/NEJMoa1716948
   PubMed Web of Science ®Google Scholar
• Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401. doi:10.1016/S2213-2600(19)30084-0
   PubMed Web of Science ®Google Scholar
• Lu S, Wu L, Jian H, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023;11(7):624–636. doi:10.1016/S2213-2600(23)00135-2
   PubMed Web of Science ®Google Scholar
• Mok TS, Nakagawa K, Park K, et al. LBA8 Nivolumab (NIVO)+ chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722. Ann Oncol. 2022;33:S1561.
   Google Scholar
• Yang JC, Lee DH, Lee JS, et al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: phase 3 KEYNOTE-789 study. J Clin Oncol. 2023;41(17):1.
   PubMed Web of Science ®Google Scholar
• Planchard D, Janne P, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023;389(21):1935–1948. doi:10.1056/NEJMoa2306434
   PubMed Web of Science ®Google Scholar
• Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 2019;30(5):839–844. doi:10.1093/annonc/mdz077
   PubMed Web of Science ®Google Scholar
• Madeddu C, Donisi C, Liscia N, Lai E, Scartozzi M, Maccio A. EGFR-mutated non-small cell lung cancer and resistance to immunotherapy: role of the tumor microenvironment. Int J Mol Sci. 2022;23:12.
   Web of Science ®Google Scholar
• Qiao M, Jiang T, Liu X, et al. Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn? J Thorac Oncol. 2021;16(8):1267–1288. doi:10.1016/j.jtho.2021.04.003
   PubMed Web of Science ®Google Scholar
• Offin M, Rizvi H, Tenet M, et al. Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin Cancer Res. 2019;25(3):1063–1069. doi:10.1158/1078-0432.CCR-18-1102
   PubMed Web of Science ®Google Scholar
• Chen J, Facchinetti F, Braye F, et al. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients. Ann Oncol. 2022;33(4):434–444. doi:10.1016/j.annonc.2022.01.004
   PubMed Web of Science ®Google Scholar
• Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer. 2016;102:122–134. doi:10.1016/j.lungcan.2016.10.010
   PubMed Web of Science ®Google Scholar
• Masuda K, Horinouchi H, Tanaka M, et al. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. J Cancer Res Clin Oncol. 2021;147(1):245–251. doi:10.1007/s00432-020-03329-0
   PubMed Web of Science ®Google Scholar
• Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871–882. doi:10.1038/nrc3627
   PubMed Web of Science ®Google Scholar
• Xu L, Nilsson MB, Saintigny P, et al. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1 alpha in non-small cell lung cancer cells. Oncogene. 2010;29(18):2616–2627. doi:10.1038/onc.2010.16
   PubMed Web of Science ®Google Scholar
• Jackson AL, Zhou B, Kim WY. HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin Ther Targets. 2010;14(10):1047–1057. doi:10.1517/14728222.2010.511617
   PubMed Web of Science ®Google Scholar
• Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol. 2021;16(2):205–215. doi:10.1016/j.jtho.2020.10.006
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 2001;7(5):1459–1465.
   PubMed Web of Science ®Google Scholar